The role of checkpoints in the treatment of GBM

Jennifer E. Kim, Michael Lim

Research output: Contribution to journalReview articlepeer-review


Targeted immunotherapy is founded on the principle that augmentation of effector T cell activity in the tumor microenvironment can translate to tumor regression. Targeted checkpoint inhibitors in the form of agonist or antagonist monoclonal antibodies have come to the fore as a promising strategy to activate systemic immunity and enhance T cell activity by blocking negative signals, enhancing positive signals, or altering the cytokine milieu. This review will examine several immune checkpoints and checkpoint modulators that play a role in cancer pathogenesis, with an emphasis on malignant gliomas.

Original languageEnglish (US)
Pages (from-to)413-423
Number of pages11
JournalJournal of neuro-oncology
Issue number3
StatePublished - Jul 23 2015


  • CTLA-4
  • Glioblastoma multiforme
  • Immune checkpoint
  • PD-1

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research


Dive into the research topics of 'The role of checkpoints in the treatment of GBM'. Together they form a unique fingerprint.

Cite this